Fact CheckerSign in

NCT06861231Completed

Combined tDCS and Cognitive Training in Alzheimer's

Combined Intervention Using Transcranial Direct Current Stimulation and Cognitive Training in Alzheimer's Type Dementia Patients

Source: ClinicalTrials.gov · Last updated 16 Jun 2026

Brief summary (registry, in English)

The General Objective of the study is to evaluate the short- and long-term efficacy of combining transcranial Direct Current Stimulation (tDCS) and cognitive training (CT) in patients with mild cognitive impairment due to Alzheimer's disease. A randomized, single-blind, placebo-controlled design will be applied. An inter-subject design with two groups will be used: a. Active tDCS + concurrent CT and b. Sham tDCS + concurrent CT. Evaluations will be taken at pre-test, post-test, and follow-up one month later. The hypothesis comparing active and sham tDCS with concurrent CT is that, although both groups should improve due to concurrent CT, it is expected that the active tDCS group will show significantly greater improvements in post-treatment. Additionally, these improvements should be maintained in the long-term follow-up in the active tDCS group, while in the sham tDCS group, a partial loss of gains is expected at follow-up. Transcranial Direct Current Stimulation (tDCS): HDC stimulators (Newronika TM, Milan, Italy) will be used. For active stimulation, the current intensity will be constant at 2 mA, with a stimulation time of 20 minutes daily for 10 days, and an initial and final ramp of 30 seconds. For the placebo group, current will only be applied during the initial and final ramps to generate the sensation of active stimulation. A neoprene cap with carbon rubber electrodes and sponges soaked in saline solution (5 x 5 cm) will be used. The anode will be placed over the left dorsolateral prefrontal cortex (DLPFC), and the cathode over the right supraorbital area (rSO). Cognitive Training (CT): The CT will consist of 10 sessions of 50 minutes each, based on tasks involving executive functions and memory, including categorization, answering questions, short stories, problem-solving, recalling autobiographical moments, planning simple tasks, and schedule analysis.

Status (registry)
Completed
Study type
Interventional
Enrollment
22 (actual)
First submitted
28 Feb 2025
Start date
4 Oct 2024
Primary completion date
14 Mar 2026
Lead sponsor
University of Valencia
NCT number
NCT06861231

What you commit to

  • Study type: Interventional
  • Participants enrolled: 22
  • From 4 Oct 2024 to the primary completion date, 14 Mar 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Criteria the registry did not label

  • Participants were eligible if they met criteria for mild cognitive impairment due to Alzheimer's disease (MCI due to AD), defined as a score ≥ 23 on the Mini-Mental State Examination (MMSE) and classification at Stage 3 on the Global Deterioration Scale (GDS).

Age in the registry: 60 years to 90 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Universidad de Valencia
Coordinator of this site? Confirm its status
ValenciaSpainUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.